113 related articles for article (PubMed ID: 15182177)
21. Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic.
Shi ZD; Karki RG; Oishi S; Worthy KM; Bindu LK; Dharmawardana PG; Nicklaus MC; Bottaro DP; Fisher RJ; Burke TR
Bioorg Med Chem Lett; 2005 Mar; 15(5):1385-8. PubMed ID: 15713392
[TBL] [Abstract][Full Text] [Related]
22. Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2.
García-Echeverría C; Furet P; Gay B; Fretz H; Rahuel J; Schoepfer J; Caravatti G
J Med Chem; 1998 May; 41(11):1741-4. PubMed ID: 9599224
[No Abstract] [Full Text] [Related]
23. Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
Oishi S; Karki RG; Kang SU; Wang X; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
J Med Chem; 2005 Feb; 48(3):764-72. PubMed ID: 15689160
[TBL] [Abstract][Full Text] [Related]
24. Sprouty2 binds Grb2 at two different proline-rich regions, and the mechanism of ERK inhibition is independent of this interaction.
Martínez N; García-Domínguez CA; Domingo B; Oliva JL; Zarich N; Sánchez A; Gutiérrez-Eisman S; Llopis J; Rojas JM
Cell Signal; 2007 Nov; 19(11):2277-85. PubMed ID: 17689925
[TBL] [Abstract][Full Text] [Related]
25. Concise and enantioselective synthesis of Fmoc-Pmp(But)2-OH and design of potent Pmp-containing Grb2-SH2 domain antagonists.
Li P; Zhang M; Peach ML; Liu H; Yang D; Roller PP
Org Lett; 2003 Aug; 5(17):3095-8. PubMed ID: 12916990
[TBL] [Abstract][Full Text] [Related]
26. Structural insight into the binding diversity between the human Nck2 SH3 domains and proline-rich proteins.
Liu J; Li M; Ran X; Fan JS; Song J
Biochemistry; 2006 Jun; 45(23):7171-84. PubMed ID: 16752908
[TBL] [Abstract][Full Text] [Related]
27. Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands.
Shi ZD; Wei CQ; Lee K; Liu H; Zhang M; Araki T; Roberts LR; Worthy KM; Fisher RJ; Neel BG; Kelley JA; Yang D; Burke TR
J Med Chem; 2004 Apr; 47(8):2166-9. PubMed ID: 15056012
[TBL] [Abstract][Full Text] [Related]
28. Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains.
de Mol NJ; Dekker FJ; Broutin I; Fischer MJ; Liskamp RM
J Med Chem; 2005 Feb; 48(3):753-63. PubMed ID: 15689159
[TBL] [Abstract][Full Text] [Related]
29. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
[TBL] [Abstract][Full Text] [Related]
30. Modelling of the complex between a 15-residue peptide from mSos2 and the N-terminal SH3 domain of Grb2 by molecular-dynamics simulation.
Calero S; Lago S; van Gunsteren WF; Daura X
Chem Biodivers; 2004 Mar; 1(3):505-19. PubMed ID: 17191865
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity.
Shi ZD; Liu H; Zhang M; Worthy KM; Bindu L; Yang D; Fisher RJ; Burke TR
Bioorg Med Chem; 2005 Jul; 13(13):4200-8. PubMed ID: 15893931
[TBL] [Abstract][Full Text] [Related]
32. A miniprotein scaffold used to assemble the polyproline II binding epitope recognized by SH3 domains.
Cobos ES; Pisabarro MT; Vega MC; Lacroix E; Serrano L; Ruiz-Sanz J; Martinez JC
J Mol Biol; 2004 Sep; 342(1):355-65. PubMed ID: 15313630
[TBL] [Abstract][Full Text] [Related]
33. Hairpin peptide beacon: dual-labeled PNA-peptide-hybrids for protein detection.
Thurley S; Röglin L; Seitz O
J Am Chem Soc; 2007 Oct; 129(42):12693-5. PubMed ID: 17927187
[No Abstract] [Full Text] [Related]
34. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and utilization of chiral alpha-methylated alpha-amino acids with a carboxyalkyl side chain in the design of novel Grb2-SH2 peptide inhibitors free of phosphotyrosine.
Long YQ; Xue T; Song YL; Liu ZL; Huang SX; Yu Q
J Med Chem; 2008 Oct; 51(20):6371-80. PubMed ID: 18821748
[TBL] [Abstract][Full Text] [Related]
36. Utilization of a common pathway for the synthesis of high affinity macrocyclic Grb2 SH2 domain-binding peptide mimetics that differ in the configuration at one ring junction.
Shi ZD; Karki RG; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
Chem Biodivers; 2005 Apr; 2(4):447-56. PubMed ID: 17191992
[TBL] [Abstract][Full Text] [Related]
37. Peptoid architectures: elaboration, actuation, and application.
Yoo B; Kirshenbaum K
Curr Opin Chem Biol; 2008 Dec; 12(6):714-21. PubMed ID: 18786652
[TBL] [Abstract][Full Text] [Related]
38. Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors.
Nguyen JT; Turck CW; Cohen FE; Zuckermann RN; Lim WA
Science; 1998 Dec; 282(5396):2088-92. PubMed ID: 9851931
[TBL] [Abstract][Full Text] [Related]
39. Exploring the systematic effect of N-substituted PxxP motifs on peptoid affinity to ARHGEF5/TIM SH3 domain and its relationship with ARHGEF5/TIM activation.
Fu Y; He P; Zhou Y; Huang S; Liang L; Liu S
Proteins; 2019 Nov; 87(11):979-991. PubMed ID: 31197859
[TBL] [Abstract][Full Text] [Related]
40. 4-Fluoroproline derivative peptides: effect on PPII conformation and SH3 affinity.
Ruzza P; Siligardi G; Donella-Deana A; Calderan A; Hussain R; Rubini C; Cesaro L; Osler A; Guiotto A; Pinna LA; Borin G
J Pept Sci; 2006 Jul; 12(7):462-71. PubMed ID: 16506148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
